Is it safe to start Jardiance (Empagliflozin) 25 mg daily and metformin 1000 mg sustained action (SA) daily in a patient with a high Hemoglobin A1c (HbA1c) level and refusal of insulin therapy, without concern for hypoglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yes, you can safely start Jardiance 25 mg daily and metformin 1000 mg SA daily without significant concern for hypoglycemia in this patient with A1c 11.7% who refuses insulin.

Hypoglycemia Risk Assessment

The combination of empagliflozin (Jardiance) and metformin carries minimal hypoglycemia risk because neither medication directly stimulates insulin secretion. 1, 2

  • Metformin works by reducing hepatic glucose production and improving insulin sensitivity—it does not cause hypoglycemia when used alone 3
  • Empagliflozin (SGLT-2 inhibitor) works by increasing urinary glucose excretion independent of insulin, resulting in extremely low hypoglycemia rates 1, 4
  • In clinical trials of empagliflozin 25 mg added to metformin, documented symptomatic hypoglycemia occurred in only 1.6-3.8% of patients, with no episodes requiring assistance 1, 4, 5

Appropriateness of This Regimen for Severe Hyperglycemia

While this combination is safe from a hypoglycemia standpoint, you should counsel the patient that with an A1c of 11.7%, insulin therapy would be the most effective treatment and this refusal may delay optimal glycemic control. 3

  • Guidelines recommend considering insulin for patients with marked hyperglycemia (A1C ≥8.5%) from the outset 3, 6
  • However, when insulin is refused, initiating dual therapy with metformin plus an SGLT-2 inhibitor is a reasonable alternative that can achieve meaningful A1c reductions 1, 4, 5

Expected Efficacy

This combination should reduce A1c by approximately 1.5-2.1% over 24 weeks:

  • Empagliflozin 25 mg added to metformin reduces A1c by 0.6-0.8% 1
  • When started as initial combination therapy in treatment-naïve patients with baseline A1c 8.6-8.9%, empagliflozin 25 mg + metformin 2000 mg reduced A1c by 2.1% 1, 5
  • This would bring your patient's A1c from 11.7% to approximately 9.6-10.2%—still above target but a meaningful improvement 1, 5

Dosing Considerations

Start metformin at a lower dose and titrate upward to minimize gastrointestinal side effects:

  • Begin with metformin 500 mg daily with the largest meal, then increase by 500 mg weekly as tolerated up to 1000 mg twice daily (2000 mg total) 6
  • Empagliflozin 25 mg can be started immediately at full dose as it does not require titration 1
  • Check renal function (eGFR) before starting—metformin requires eGFR ≥30 mL/min/1.73 m² and empagliflozin is most effective with eGFR ≥45 mL/min/1.73 m² 6, 1

Critical Monitoring and Follow-Up

Reassess A1c in 3 months and prepare to intensify therapy if target is not approached:

  • Monitor for volume depletion and genital mycotic infections (common with SGLT-2 inhibitors) 1
  • Check vitamin B12 levels annually on long-term metformin therapy 6
  • If A1c remains >9% after 3-6 months on this regimen, strongly reconsider insulin therapy or add a GLP-1 receptor agonist 3, 7

Common Pitfalls to Avoid

  • Do not add a sulfonylurea to this regimen—it would introduce significant hypoglycemia risk and cause weight gain 2
  • Do not delay treatment intensification beyond 3-6 months if glycemic targets are not approached—therapeutic inertia at this level of hyperglycemia increases complication risk 7
  • Ensure the patient understands this is a compromise approach and that insulin remains the gold standard for severe hyperglycemia 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.